Fosun Pharma USA and MAP International have joined forces in a global initiative aimed at improving access to essential pain relief medications in marginalized communities. This partnership involves Fosun Pharma USA donating ketorolac tromethamine injection, a vital non-opioid pain medication, through MAP International’s distribution network that serves 300 grassroots partners and volunteer medical groups worldwide. The focus is on addressing the gap in pain management accessibility, particularly in regions with limited medical resources and medication shortages. Ketorolac tromethamine, widely used for moderate to severe pain in surgical, post-operative, and trauma care scenarios, is particularly beneficial due to its injectable formulation, making it suitable for rural clinics, mobile units, and emergency response situations.
The collaboration between Fosun Pharma USA and MAP International is rooted in the belief that health equity is a fundamental human right, contributing to the resilience and well-being of communities globally. Fosun Pharma USA’s commitment to ensuring high-quality healthcare access aligns perfectly with MAP International’s mission of providing medicine to individuals worldwide, regardless of their geographical location. MAP International, in 2024 alone, distributed over 47 million treatments to 92 countries, offering critical support for emergency situations, surgical needs, and essential care for individuals and families, thereby fostering economic growth, workforce productivity, and overall well-being.
Chris Palombo, the President and CEO of MAP International, emphasizes that access to pain relief transcends mere medical necessity; it embodies dignity, healing, and compassion. The donation from Fosun Pharma USA enables MAP International to cater to patients recovering from surgeries, childbirth, or disasters, ensuring that pain relief remains a fundamental aspect of medical care. By combining the resources and purpose of both organizations, Fosun Pharma USA and MAP International are turning surplus medication into a valuable asset that alleviates suffering, aids in recovery, and instills hope in those in need.
Furthermore, Fosun Pharma USA is actively involved in the marketing of a diverse range of specialty injectable pharmaceuticals and ophthalmic products, with plans to expand into branded therapeutics targeting oncology, autoimmune disorders, and central nervous system conditions. This expansion underscores the company’s commitment to innovation and improving healthcare outcomes for a broader patient population. The collaboration between Fosun Pharma USA and MAP International exemplifies the power of strategic partnerships in driving impactful change, underscoring the transformative potential of aligning corporate resources with humanitarian goals.
Key Takeaways:
– The collaboration between Fosun Pharma USA and MAP International aims to bridge the gap in pain relief accessibility in underserved communities globally.
– Ketorolac tromethamine injection, a non-opioid pain reliever, is being donated by Fosun Pharma USA to aid in addressing the pain management needs of marginalized populations.
– MAP International’s extensive distribution network ensures that the donated medications reach grassroots partners and volunteer medical groups in over 90 countries, supporting emergency responses and essential care.
– The partnership highlights the significance of combining corporate resources with humanitarian missions to create meaningful impact and improve health outcomes for vulnerable populations.
Tags: formulation
Read more on drugstorenews.com